IL-23 Receptor (IL-23R) Gene Protects Against Pediatric Crohn's Disease
Overview
Authors
Affiliations
Background: The IL-23 receptor (IL-23R) has been found to be associated with small bowel Crohn's disease (CD) in a whole genome association study. Specifically, the rare allele of the R381Q single nucleotide polymorphism (SNP) conferred protection against CD. It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients.
Methods: DNA was collected from 609 subjects (151 CD and 52 ulcerative colitis [UC] trios). Trios were genotyped for the R381Q SNP of the IL-23R gene and SNP8, SNP12, SNP13, of the CARD15 gene using Taqman. The transmission disequilibrium test (TDT) was used for association to disease using GENEHUNTER 2.0.
Results: The rare allele of R381Q SNP was present in 2.7% of CD and 2.9% UC probands. The CARD15 frequency was 31.5% (CD) and 18% (UC). The IL-23R allele was negatively associated with inflammatory bowel disease (IBD): the R381Q SNP was undertransmitted in children with IBD (8 transmitted [T] versus 27 untransmitted [UT]; P = 0.001). This association was significant for all CD patients (6 T versus 19 UT; P = 0.009), especially for non-Jewish CD patients (2 T versus 17 UT; P = 0.0006). TDT showed a borderline association for UC (2 T versus 8 UT; P = 0.06). As expected, CARD15 was associated with CD in children by the TDT (58 T versus 22 UT P = 0.00006), but not with UC.
Conclusions: The protective IL-23R R381Q variant was particularly associated with CD in non-Jewish children. Thus, the initial whole genome association study based on ileal CD in adults has been extended to the pediatric population and beyond small bowel CD.
Audia S, Brescia C, Dattilo V, Torchia N, Trapasso F, Amato R Cancers (Basel). 2025; 17(1.
PMID: 39796684 PMC: 11718844. DOI: 10.3390/cancers17010055.
Konecny A, Shows D, Lord J PLoS One. 2023; 18(11):e0285918.
PMID: 37922286 PMC: 10624325. DOI: 10.1371/journal.pone.0285918.
The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease.
Korta A, Kula J, Gomulka K Int J Mol Sci. 2023; 24(12).
PMID: 37373318 PMC: 10299037. DOI: 10.3390/ijms241210172.
All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective.
Jefremow A, Neurath M Immunotargets Ther. 2020; 9:289-297.
PMID: 33274187 PMC: 7705252. DOI: 10.2147/ITT.S282466.
Gpr109a Limits Microbiota-Induced IL-23 Production To Constrain ILC3-Mediated Colonic Inflammation.
Bhatt B, Zeng P, Zhu H, Sivaprakasam S, Li S, Xiao H J Immunol. 2018; 200(8):2905-2914.
PMID: 29514953 PMC: 5893356. DOI: 10.4049/jimmunol.1701625.